Substance / Medication

Vilanterol trifenatate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Research Evidence

Published studies and systematic reviews

Sort:
24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids.
Lötvall Jan, Bateman Eric D, Bleecker Eugene R et al. · Eur Respir J · 2012
PMID: 22362859RCT
Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy.
Albertson Timothy E, Bullick Samuel W, Schivo Michael et al. · Drug Des Devel Ther · 2016
PMID: 28008228ReviewFull text (PMC)
The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience.
Albertson Timothy E, Richards John R, Zeki Amir A · Ther Adv Respir Dis · 2016
PMID: 26668137ReviewFull text (PMC)
Vilanterol trifenatate for the treatment of COPD.
Malerba Mario, Radaeli Alessandro, Montuschi Paolo et al. · Expert Rev Respir Med · 2016
PMID: 27143334Review
Enantiomeric separation of vilanterol trifenatate by chiral liquid chromatography.
Guo Yajun, Yang Yulei, Peng Jiajuan et al. · Chirality · 2019
PMID: 31392772Other
Fluticasone furoate and vilanterol trifenatate combination therapy for the treatment of asthma.
Gray Emma L, Chang Vicky, Thomas Paul S · Expert Rev Respir Med · 2016
PMID: 27221165Other

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Vilanterol trifenatate (substance)
SNOMED CT
702409007
UMLS CUI
C3644419

Clinical Data

This intervention maps to 7 entities in the Healos knowledge graph.

1
Conditions
2
Biomarkers
3
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.